<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049123</url>
  </required_header>
  <id_info>
    <org_study_id>16644</org_study_id>
    <secondary_id>I8B-MC-ITRY</secondary_id>
    <nct_id>NCT04049123</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 in Healthy Chinese Participants</brief_title>
  <official_title>A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Following Single Dose Administration in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which
      is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and
      the affect of LY900014 on blood sugar levels. For each participant, the study will consist of
      3 periods and will last about 51 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Insulin Lispro Area under the Serum Concentration Versus Time Curve from Time Zero to 10 hours Postdose (AUC[0-10h])</measure>
    <time_frame>Day 1: Predose through 600 minutes postdose in each period</time_frame>
    <description>PK: Insulin Lispro AUC(0-10h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Day 1: Predose through 600 minutes postdose in each period</time_frame>
    <description>PD: Gtot</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Insulin Lispro (Humalog)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900014 administered once, SC, in two of three study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro (Humalog)</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Lispro (Humalog)</arm_group_label>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy native Chinese males or females

          -  Female participants:

               -  Women of child-bearing potential who are abstinent or use effective methods of
                  contraception for the entirety of the study.

               -  Women not of child-bearing potential who are infertile or post-menopausal

          -  Have a body mass index (BMI) of 18 to 28 kilograms per square meter (kg/mÂ²)

          -  Are nonsmokers

          -  Have a fasting plasma glucose value &gt;71 milligrams per deciliter (mg/dL) (3.9
             millimoles per liter [mmol/L]) and &lt;108 mg/dL (6.0 mmol/L)

        Exclusion Criteria:

          -  Are currently enrolled in a clinical study, or have participated, within the last 30
             days, in a clinical study involving an investigational product

          -  Have previously completed or withdrawn from this study or any other study
             investigating LY900014

          -  Have known allergies to LY900014 or any components of the formulation

          -  Have a significant history of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the investigational product; or of interfering with
             the interpretation of data

          -  Intend to use over-the-counter or prescription medication within 7 and 14 days,
             respectively, prior to dosing or during the study.

          -  Have donated blood of more than 400 milliliters (mL) within the previous 6 months of
             study screening or donated more than 100 mL within the last 30 days.

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>86285583231</phone>
    </contact>
    <investigator>
      <last_name>Yerong Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 1, 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

